Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer

KRAS is one of the driver oncogenes in non-small-cell lung cancer (NSCLC) but remains refractory to current modalities of targeted pathway inhibition, which include inhibiting downstream kinase MEK to circumvent KRAS activation. Here, we show that pulsatile, rather than continuous, treatment with ME...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Rep
Hauptverfasser: Choi, Hyejin, Deng, Jiehui, Li, Shuai, Silk, Tarik, Dong, Lauren, Brea, Elliott J., Houghton, Sean, Redmond, David, Zhong, Hong, Boiarsky, Jonathan, Akbay, Esra A., Smith, Paul D., Merghoub, Taha, Wong, Kwok-Kin, Wolchok, Jedd D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6719696/
https://ncbi.nlm.nih.gov/pubmed/30995478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2019.03.066
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge